Gefitinib: Current status in the treatment of non-small cell lung cancer

Drugs of Today

Volumn 40, Issue 10, 2004, Pages 809-827

  Tanović, Adnan ^a   Alfaro, Vicente ^a  

^a Prous Science ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BICARBONATE; CIMETIDINE; CISPLATIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; ITRACONAZOLE; KETOCONAZOLE; LOPERAMIDE; NAVELBINE; OROSOMUCOID; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; RANITIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ACNE; ADVANCED CANCER; ANGIOGENESIS; ANOREXIA; APOPTOSIS; AREA UNDER THE CURVE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; DRY SKIN; ENZYME ACTIVATION; GENE MUTATION; HUMAN; INTERSTITIAL LUNG DISEASE; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; MULTIPLE DRUG DOSE; NAUSEA; NONHUMAN; OUTCOMES RESEARCH; PAIN; PHARMACODYNAMICS; PHARMACOKINETICS; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PRURITUS; RASH; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOMNOLENCE; SURVIVAL RATE; TREATMENT FAILURE; VOMITING;

CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; LUNG NEOPLASMS; MOLECULAR STRUCTURE; QUINAZOLINES;

EID: 8744315596     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2004.40.10.863742     Document Type: Review

References (70)

1. Fossella, F.V., Lee, J.S., Hong, W.K. Management strategies for recurrent non-small cell lung cancer. Semin Oncol 1997, 24: 455-62.
2. Schiller, J.H., Harrington, D., Belani, C.P. et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346: 92-8.
3. Massarelli, E., Andre, F., Liu, D.D. et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003, 39: 55-61.
4. Herbst, R.S., Kies, M.S. ZD1839 (Iressa) in non-small cell lung cancer. Oncologist 2002, 7 (Suppl. 4): 9-15.
5. Shepherd, F.A., Dancey, J., Ramlau, R. et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based therapy. J Clin Oncol 2001, 18: 2095-103.
6. Vlahovic, G., Crawford, J. Activation of tyrosine kinases in cancer. Oncologist 2003, 8: 531-8.
7. Ranson, M. ZD1839 (Iressa): For more than just non-small cell lung cancer. Oncologist 2002, 7 (Suppl. 4): 16-24.
8. Glover, K.Y., Perez-Soler, R., Papadimitradopoulou, V.A. A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancer. Semin Oncol 2004, 31: 83-92.
9. Slichenmyer, W.J., Fry, D.W. Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin Oncol 2001, 28: 67-79.
10. Klijn, J.G., Berns, P.M., Schmitz, P.I., Foekens, J.A. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992, 13: 3-17.
11. Walker, R.A., Dearing, S.J. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat 1999, 53: 167-76.
12. Beckmann, M.W., Niederacher, D., Massenkeil, G. et al. Expression analyses of epidermal growth factor receptor and HER-2/neu: No advantage of prediction of recurrence or survival in breast cancer patients. Oncology 1996, 53: 441-7.
13. Olayioye, M.A., Neve, R.M., Lane, H.A., Hynes, N.E. The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 2000, 19: 3159-67.
14. Kurie, J.M., Shin, H.J., Lee, J.S. et al. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 1996, 2: 1787-93.
15. Kelloff, G.J., Fay, J.R., Steele, V.E. et al. Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1996, 5: 657-66.
16. Arteaga, C.L. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002, 7 (Suppl. 4): 31-9.
17. AstraZeneca. Iressa™, tablets 250 mg. Anti-cancer drug/epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (Gefitinib tablets label), 2003.
18. Ranson, M., Hammond, L.A., Ferry, D. et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol 2002, 20: 2240-50.
19. Swaisland, H., Laight, A., Stafford, L. et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin Pharmacokinet 2001, 40: 297-306.
20. Herbst, R.S., Maddox, A.M., Rothenberg, M.L. et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002, 20: 3815-25.
21. Baselga, J., Rischin, D., Ranson, M. et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002, 20: 4292-302.
22. McKillop, D. et al. Intratumoral and plasma concentrations of gefitinib in breast cancer patients: Preliminary results from a presurgical investigatory study (BCIRG 103). American Society for Clinical Oncology (June 5-7, New Orleans) 2004, Abstr. 581.
23. Culy, C.R., Faulds, D. Gefitinib. Drugs 2002, 62: 2237-48, discussion 2249-50.
24. Cohen, M.H., Williams, G.A., Sridhara, R. et al. United States Food and Drug Administration. Drug approval summary: Gefitinib (ZD1839, Iressa) tablets. Clin Cancer Res 2004, 10: 1212-8.
25. Swaisland, H., Smith, R.P., Farebrother, J. The effect of the induction and inhibition of CYP3A4 on the pharmacokinetics of single doses of ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinases inhibitor (EGFR-TK) in healthy male volunteers (Abstr. 328). 38th Proc Am Soc Clin Oncol 2003.
26. Twelves, C., White, J., Harris, A. A phase I pharmacokinetic and tolerability trial of ZD1839 (Iressa) in hepatically impaired patients with solid tumors (Abstr. 339). 38th Proc Am Soc Clin Oncol 2002.
27. Cappuzzo, F., Bartolini, S., Ceresoli, G.L. et al. Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). Br J Cancer 2004, 90: 82-6.
28. Gridelli, C., Maione, P., Castaldo, V., Rossi, A. Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer. Br J Cancer 2003, 89: 1827-9.
29. Ochs, J., Grous, J.J., Warner, K.L. Final survival and safety results for 21,064 non-small-cell lung cancer (NSCLC) patients who received compassionate use gefitinib in a U.S. expanded access program (EAP). American Society for Clinical Oncology Annual Meeting (June 5-7, New Orleans) 2004, Abstr. 7060.
30. Fukuoka, M., Yano, S., Giaccone, G. et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003, 21: 2237-46.
31. Kris, M.G., Natale, R.B., Herbst, R.S. et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003, 290: 2149-58.
32. Elsayed, Y.A., Sausville, E.A. Selected novel anticancer treatments targeting cell signaling proteins. Oncologist 2001, 6: 517-37.
33. Wakeling, A.E., Guy, S.P., Woodburn, J.R. et al. ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002, 62: 5749-54.
34. Ciardiello, F., Caputo, R., Bianco, R. et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001, 7: 1459-65.
35. Krause, M., Baumann, M., Thames, H.D. In: Regard to Solomon et al. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. IJROBP 2003, 55: 713-23. Int J Radiat Oncol Biol Phys 2003, 57: 300-1, author reply 301.
36. Krause, M., Baumann, M., Thames, H.D. In: Regard to Solomon et al. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. IJROBP 2003, 55: 713-23. Int J Radiat Oncol Biol Phys 2003, 57: 300-1, author reply 301.
37. Sirotnak, F.M., Zakowski, M.F., Miller, V.A., Scher, H.I., Kris, M.G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase Clin Cancer Res 2000, 6: 4885-92.
38. Sirotnak, F.M. Studies with ZD1839 in preclinical models. Semin Oncol 2003, 30: 12-20.
39. Ciardiello, F., Caputo, R., Bianco, R. et al. Anti-tumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000, 6: 2053-63.
40. Chan, K.C., Knox, W.F., Gandhi, A., Slamon, D.J., Potten, C.S., Bundred, N.J. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. Br J Surg 2001, 88: 412-8.
41. Bundred, N.J., Chan, K., Anderson, N.G. Studies of epidermal growth factor receptor inhibition in breast cancer. Endocr Relat Cancer 2001, 8: 183-9.
42. Williams, K.J., Telfer, B.A., Stratford, I.J., Wedge, S.R. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 2002, 86: 1157-61.
43. Bianco, C., Tortora, G., Bianco, R. et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002, 8: 3250-8.
44. Xu, J.M., Azzariti, A., Colucci, G., Paradiso, A. The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. Cancer Chemother Pharmacol 2003, 52: 442-8.
45. Ciardiello, F., Caputo, R., Borriello, G. et al. ZD 1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int J Cancer 2002, 98: 463-9.
46. Tortora, G., Caputo, R., Damiano, V. et al. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity. Clin Cancer Res 2003, 9: 866-71.
47. Albanell, J., Rojo, F., Averbuch, S. et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002, 20: 110-24.
48. Daneshmand, M., Parolin, D.A., Hirte, H.W. et al. A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clin Cancer Res 2003, 9: 2457-64.
49. Miller, A.B., Hoogstraten, B., Staquet, M., Winkler, A. Reporting results of cancer treatment. Cancer 1981, 47: 207-14.
50. Therasse, P., Arbuck, S.G., Eisenhauer, E.A. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92: 205-16.
51. Response evaluation criteria in solid tumors (RECIST) quick reference. http://www.nci.gov/bip/RECIST.htm
52. Green, S., Weiss, G.R. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992, 10: 239-53.
53. Nakagawa, K., Tamura, T., Negoro, S. et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 2003, 14: 922-30.
54. Santoro, A., Cavina, R., Latteri, F. et al. Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer. Ann Oncol 2004, 15: 33-7.
55. Herbst, R.S. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. Semin Oncol 2003, 30: 30-8.
56. Natale, R., Skarin, A., Maddox, A. et al. Improvements in symptoms and quality of life for advanced non-small cell lung cancer pateints receiving ZD1839 (Iressa) in IDEAL 2. American Society for Clinical Oncology Annual Meeting (May 18-21, Orlando) 2002.
57. Yano, S., Kanematsu, T., Miki, T. et al. A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ("Iressa"). Cancer Sci 2003, 94: 453-8.
58. West, H., Franklin, W., Gumerlock, P. Gefitinib (ZD 1839) therapy for advanced bronchiolo-alveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. American Society for Clinical Oncology Annual Meeting (June 5-7, New Orleans) 2004, Abstr. 7014.
59. Miller, V.A., Johnson, D.H., Krug, L.M. et al. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. J Clin Oncol 2003, 21: 2094-100.
60. Giaccone, G., Gonzalez-Larriba, J.L., van Oosterom, A.T. et al. Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. Ann Oncol 2004, 15: 831-8.
61. Giaccone, G., Johnson, D.H., Manegold, C. et al. A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapynaive patients with advanced non-small-cell lung cancer (INTACT 1). Ann Oncol 2002, 13: 2-3.
62. Herbst, R.S., Giaccone, G., Schiller, J.H. et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 2004, 22: 785-94.
63. Hammond, L.A. Pharmacokinetic evaluation of gefitinib when administered with chemotherapy. Clin Lung Cancer 2003, 5 (Suppl. 1): S18-21.
64. Baselga, J. Combining the Anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: How do we go from INTACT to impact? J Clin Oncol 2004, 22: 759-61.
65. Perez-Soler, R. The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clin Cancer Res 2004, 10 (12 Pt 2): 4238s-4240s.
66. Rowinsky, E.K. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents. Drugs 2000, 60: 1: 1-14.
67. Cohen, M.H., Williams, G.A., Sridhara, R., Chen, G., Pazdur, R. FDA drug approval summary: Gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003, 8: 303-6.
68. Salomon, D.S., Brandt, R., Ciardiello, F., Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19: 183-232.
69. Kelly, K., Averbuch, S. Gefitinib: Phase II and III results in advanced non-small cell lung cancer. Semin Oncol 2004, 31: 93-9.
70. Sordell, R., Bell, D.W., Haber, D.A., Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305: 1163-7.